Genomas: Battling Side Effects with PhysioTypes by McDonald, Jessica
187
YALE JOURNAL OF BIOLOGY AND MEDICINE 80 (2007), pp.187-190.
Copyright © 2007.
PROFILE
Genomas: Battling Side Effects
with PhysioTypes
Jessica McDonald
Yale University School of Medicine, New Haven, Connecticut
In a building nearly 80 years old
tucked on the campus of Hartford Hospital
in Hartford, Connecticut, the biotechnology
company Genomas has a surprising amount
of wall space dedicated to art. In one cor-
ner, the startling whiteness is interrupted by
Gene Collage #1, in which microarray data
has been transformed into a modernist-style
collection of colorized squares. Removed
from this impromptu gallery space, the
walls resume their institutional flavor, and
a pair of large doors open to reveal a lab
performing state-of-the-art science. It is
here that the red, white, and black land-
scape of the artwork is fully realized in nan-
otechnological bliss: Gene chips, each the
size of a stick of gum and containing one
million single nucleotide polymorphisms or
SNPs, rest on the lab bench. Using these
DNA microarrays and other recent ad-
vances in genomics, the aptly named Geno-
mas aims to usher in the era of personalized
medicine with its trademark PhysioTypes.
Genomas was founded four years ago
by President and CEO Gualberto Ruaño,
MD PhD, whose vision for the company is
to use DNA-guided technology to help
physicians avoid dangerous and unneces-
sary side effects of drugs for patients on an
individual basis. Ruaño is a veteran of the
biotechnology sector; Genomas is his third
biotech company and is consistent with his
lifelong interest in polymorphisms. As a
graduate student at Yale University, he de-
velopedapatent for therapid sequencing of
polymorphisms that became the basis of his
first company, BIOS Laboratories, andTru-
Gene, an FDA-approved HIV manage-
ment tool currently in worldwide use.
Ruañothenbecameinterestedinpharmaco-
genetics, the sub-discipline of pharmacol-
ogy dealing with the effect of genetic
factors on drug reactions. In 1997, Ruaño
formed Genaissance and created a platform
technology that would extend beyond cy-
tochromes, the best known drug metaboliz-
ing enzymes. At Genaissance, Ruaño says
genes were viewed as “haplotypes as op-
posed to single polymorphisms,” and phar-
maceutical partners could embed this
technology in their clinical trials. While
testing drugs for efficacy and safety, re-
searchers also would evaluate genetic vari-
abilityanddetermineifgeneticcomponents
could,inpart,explainsideeffectsorprotec-
tion.Although successful, Ruaño lamented
his technology “remained used in pharma-
ceuticalR&Danddidn’tgotopatientcare.”
Determined to focus on patients, Ruaño de-
cided to found Genomas, this time is using
physiogenomic tools to directly affect the
way doctors prescribe medicine.“The model here is to work with clini-
cians identifying areas of medical need
where the medications are not working the
way they are supposed to for some people.
It’s not about a lesson on genetic hetero-
geneity or linkage disequilibrium; it really
is to guide treatment decisions,” he says.
Working in partnership with Hartford
Hospital — which provided the company its
seed investment — Genomas actively is col-
lecting select patients’ clinical information
and DNA to translate this data into medical
devices called PhysioTypes.The first step in
this process involves scanning the total
genome of patients taking a particular drug.
A proprietary algorithm can then identify
prevalent polymorphisms. Ruaño explains:
“We create basically a distribution of cases,
and genetically we co-relate the clinical re-
sponses with genetic differences. The ge-
netic differences are encoded by a series of
polymorphisms, which have a high fre-
quency in people who develop the side ef-
fect or vice-versa; there are some
polymorphisms that actually have a higher
frequency in the people who did not develop
side effects — so it’s not just risk, it’s also
protection.”
Ultimately, new patients can have their
DNA evaluated for the identified markers
and be placed on a spectrum of risk that can
be provided to physicians “in a way that is
actionable.” For instance, if a statin patient
ranks in the 90th percentile of risk for Lipi-
tor but only the 20th percentile for
Zocor, the physician can avoid the com-
mon practice of prescribing medication by
trial and error and start the patient directly
on Zocor. Even if the genomic profiling
fails to reveal a preferred medication, it can
alert both patient and doctor to the height-
ened risk, allowing for alternative interven-
tions and optimal management of the
potential side effects.
The PhysioType results, however, are
still predictions. The success rate of the
PhysioType in detecting risk for patients
who would go on and develop side effects is
approximately 85 percent, while the accu-
racy of those predicted not to have side ef-
fects is 90 percent.The PhysioType result is
not definitive, and even if it were widely
used there would still be a significant num-
ber of patients who would have to try several
drugs before they found their best match.
Nevertheless, the predictive power of the
PhysioType is an improvement on current
methods and could mean safer and less time-
consuming prescribing routines for a major-
ity of patients.
Although Genomas’ DNA-guided ap-
proach is theoretically applicable to any pa-
tient, Ruaño initially is “working on making
sure that the specific niches where we estab-
lish this technology are absolutely com-
pelling.” With funding from the National
Institutes of Health and the support of Hart-
ford Hospital, Genomas is developing Phys-
ioTypes for two core groups of medications
notorious for affecting a considerable per-
centage of their users with serious side ef-
fects: atypical antipsychotics and statins.
The atypical antipsychotics prescribed to
treat schizophrenia and bipolar disorder
often result in significant weight gain and
metabolic dysfunction leading to diabetes.
Similarly, some individuals using high doses
of statins to lower cholesterol and/or miti-
gate cardiovascular disease develop neuro-
muscular side effects.
In 2006, in cooperation with the Joslin
Diabetes Center Affiliate at New Britain
General Hospital, Genomas expanded to in-
clude diabetics managing their disease with
insulin sensitizers such asActos andAvan-
dia. Since these thiazolidinediones are
transcription factor agonists, they are prone
to exert multiple effects — in particular,
edema and heart failure — and are thus good
candidates for physiotyping.
In addition to increasing the number of
specific markets, PhysioTypes will have to
be continually updated each time a new drug
is approved by the FDA in order to include
the new drug in treatment options being
evaluated for adverse effects. Ruaño views
this as an advantage because the PhysioType
“learns from this clinical experience” and
likens the system to software versions
“where the next version has more precision
in regard to the first version.” Ruaño adds
that because the PhysioTypes are combina-
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200 patients, which will greatly speed the
learning curve.This remarkably small num-
ber of samples is possible because the side
effects are incredibly prevalent, afflicting
about 20 percent of users. A two-fold drop
in prevalence would mean twice as many
patient samples are needed to create the
PhysioType.
Accordingly, Ruaño is most interested
in side effects considered clinically inten-
sive, as opposed to the rarer and often lethal
adverse drug reactions (ADRs) such as those
that originally forced Vioxx off the market
in 2004. If certain reactions only occur in 1
in 5,000 or 10,000 patients, the PhysioTypes
will not necessarily incorporate this infor-
mation into the system. Ruaño believes,
however, there is a “connection between the
catastrophic events and the more clinically
intensive events and those have to do with
common mechanisms that underlie them
both.” Indeed, all of the drugs Genomas is
examining are accompanied by warning la-
bels — some with black box warnings — or
have been withdrawn from the market due
to safety concerns. It is possible Genomas’
technology could prevent certain drugs from
being withdrawn by limiting access to those
at risk, and it has important implications for
the pharmaceutical industry.
Beyond the concomitant identification
of theADRs, the clinically intensive side ef-
fects themselves are often disabling and re-
main a serious concern. Ruaño says these
side effects are a strain on both patients and
the healthcare system and describes an all-
too-common situation in which a patient
who came to a physician for treatment for
one disease returns with complaints engen-
dered by the necessary medication.
“Now you have other things to worry
about and diagnose and treat, and so that
triggers a series of medical transactions
where the patient has to keep coming back
… It’s the last thing you want,” he says.
If PhysioTypes are capable of eliminat-
ingevenafractionoftheseadversereactions,
notonlywillindividualpatientcareimprove,
but the burden on the already encumbered
healthcare system also will be attenuated.
In fact, it is the healthcare system that
may determine the trajectory of the Physio-
Type and the nascence of personalized med-
icine. Ruaño knows the success of his
platform will depend on its clinical utility
within the system. Practically and econom-
ically, how will this innovation become inte-
grated into the healthcare system? For now,
Ruaño’s answer is triage. Citing laparoscopy
and medical imaging, Ruaño explains that
innovations in medicine have a history of
being triaged, and he believes DNA-guided
medicine will be no different.
“When [laparoscopy] initially started
back in the 1970s — that was revolutionary.
That you would use video and robotics to
operate on people — that was really wild at
the time. And now, 30 years later, you
wouldn’t even think twice about it.”
Thus, Ruaño believes that introducing
this technology into select markets will ease
the medical community toward more ubiqui-
tous use of PhysioTypes, although it will
likely be another decade until there is a
“more profound change of how we practice
medicine.”
Whether or not PhysioTypes are the
harbingers of universal DNA-guided medi-
cine, questions abound about the proper use
and protection of an individual’s genetic
code in 21st century healthcare. According
to Ruaño, the full-fledged use of genomics
in medicine is neither ethically conscionable
nor sustainable until the healthcare system
is based on prevention and “when you can
say that because these genetic factors are
partial contributors to disease, you can do x,
y, and z to override that, in terms of
lifestyle.” Ruaño believes the ethical risk of
his PhysioTypes is relatively low because
they do not involve an entire genome scan
and the DNAis not stored. Instead, the sam-
ple is evaluated for approximately 40 mark-
ers, which can advise an optimal regimen,
and the DNAis thrown away. “We limit the
risk by measuring selected genes, and we
optimize the value so that you have a good
risk-to-reward ratio. That’s how we oper-
ate,” he says. The development of the Phys-
ioTypes does involve whole genome scans,
but these are for research purposes only.
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cerns individuals have about volunteering
their DNA and advises: “Do what you need
to do for the problem, no more, and make
sure the value justifies the risk.”
While the main goal of Genomas is to
improve clinical care, there is also the po-
tential to discover the mechanism of action
(and bystander dysfunction) of certain
drugs. Ruaño says, “We learn a lot of new
information about how these drugs work …
so from a scientific perspective already there
is knowledge that has been gathered.” For
example, in a study published in Molecular
Psychiatry last year, Ruaño and colleagues
reported that two antipsychotics may induce
pre-diabetic symptoms by two separate
mechanisms [1]. The DNA of patients on
olanzapine and risperidone was screened for
13 candidate genes and 29 SNPs, and, like a
PhysioType, this information was integrated
with the weight profiles of each patient. In-
terestingly, patients with weight gain on
olanzapine had higher frequencies of SNPs
in genes involved in peripheral lipid home-
ostasis, while those on risperidone had
higher frequencies of genes involved in
brain appetite peptide regulation. A similar
approach also was used to find a correlation
between the myalgia pain of statin patients
and two SNPs in serotonin receptors, as pub-
lished in a 2007 issue of Muscle & Nerve
[2]. While the number of patients in the
study experiencing myalgia was small and
the research does not prove causality, the
concept that serotonin receptor function is
involved in modulating pain is an intriguing
starting point for further investigation. For
Ruaño, the ability to conduct this kind of re-
search is at the core of Genomas. “Our big
paradigm change is that we learn from clin-
ical variability. We’re learning from patient
care, and we’re translating that into mecha-
nism,” he says.
The bi-directional flow of information
is part of what makes Genomas so revolu-
tionary and is captured with a stroll through
the halls — from gallery to lab and back.
The minimalist, solid blocks of color of
Gene Collage #1 are infinitely more beauti-
ful knowing they represent the potential for
a new age of medicine in which drugs work
precisely as intended.
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